Medicon Pharmaceuticals

Medicon Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of "Phospho-NSAIDs," a novel class of therapeutic agents designed to improve the safety and efficacy of conventional non-steroidal anti-inflammatory drugs (NSAIDs). By chemically modifying NSAIDs with a diethylphosphate moiety, the company creates compounds that selectively target cancer cells and inflammatory pathways while significantly reducing gastrointestinal and systemic toxicity. The lead candidate, Phospho-sulindac (OXT-328), is currently in clinical development for chemotherapy-induced peripheral neuropathy and has shown significant potential in various oncology and inflammatory indications. Medicon's pipeline also includes Phospho-valproic acid (MDC-1112) for glioblastoma and pancreatic cancer, as well as other modified molecules targeting STAT3, NF-kB, and the thioredoxin system.